Chest Medicine
RCT: Role of thoracic ultrasonography in pleurodesis pathways for malignant pleural effusions.
8 Mar, 2022 | 08:28h | UTCRole of thoracic ultrasonography in pleurodesis pathways for malignant pleural effusions (SIMPLE): an open-label, randomised controlled trial – The Lancet Respiratory Medicine (link to abstract – $ for full-text)
Commentary on Twitter
Thoracic ultrasonography-guided pleurodesis in patients with malignant pleural effusions results in shorter hospital stay without reducing the success rate of the procedure at 3 monthshttps://t.co/hof4Rd2nUt
— K Pavithran (@drkpavithran) March 2, 2022
Systematic Review: Anticoagulants for people hospitalized with COVID‐19.
7 Mar, 2022 | 00:48h | UTCAnticoagulants for people hospitalised with COVID‐19 – Cochrane Library
Related: Anticoagulation in Patients With COVID-19: JACC Review Topic of the Week.
Arterial blood gas analysis: as safe as we think? A multicentre historical cohort study.
7 Mar, 2022 | 00:00h | UTCArterial blood gas analysis: as safe as we think? A multicentre historical cohort study – ERJ Open
[Preprint] RECOVERY trial shows Baricitinib reduces deaths in patients hospitalized with COVID-19.
4 Mar, 2022 | 10:09h | UTCNews Release: RECOVERY trial shows Baricitinib reduces deaths in patients hospitalised with COVID-19 – University of Oxford
Commentaries:
Arthritis drug reduces mortality in severe COVID-19, huge clinical trial finds – Science
Another life-saving Covid drug identified – BBC
Related:
WHO recommends two new drugs (Baricitinib and Sotrovimab) to treat COVID-19.
RCT: Baricitinib reduced mortality in hospitalized adults with COVID-19.
Randomized trial: Baricitinib plus remdesivir reduce recovery time in patients with COVID-19
Commentary from the author on Twitter (thread – click for more)
RECOVERY pre-print: Baricitinib
Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis https://t.co/g0cNjaBzEL
— Martin Landray (@MartinLandray) March 3, 2022
Updated WHO guidance conditionally recommends Molnupiravir for patients with non-severe covid-19 at highest risk of hospitalization.
4 Mar, 2022 | 09:57h | UTCBMJ News Release: WHO recommends antiviral drug for patients with non-severe covid-19 at highest risk of hospital admission – BMJ
WHO News Release: WHO updates its treatment guidelines to include molnupiravir
See updated guidance: A living WHO guideline on drugs for covid-19 – BMJ
Related:
Editorial (just published): Molnupiravir’s authorisation was premature – The BMJ
FDA panel narrowly recommends authorization of first antiviral pill to treat COVID.
8 lingering questions about the new Covid pills from Merck and Pfizer.
The U.K. approves Merck’s COVID-19 antiviral pill, calling it a world first.
Merck to allow other nations to produce new COVID-19 antiviral.
Video: Merck’s Covid pill could transform treatment. Here’s how it works.
How antiviral pill Molnupiravir shot ahead in the COVID drug hunt.
What we know — and don’t know — about Merck’s new Covid-19 pill.
Merck’s Covid-19 pill is great news but may not be a game-changer.
Video | A Pill For COVID? A Doctor Explains Molnupiravir.
M-A: Efficacy of covid-19 vaccines in immunocompromised patients.
4 Mar, 2022 | 10:01h | UTCNews Release: Study suggests additional covid-19 vaccine doses for immunocompromised patients – BMJ Newsroom
Related: Response to additional COVID-19 vaccine doses in people who are immunocompromised: a rapid review.
Commentary on Twitter
NEW RESEARCH: Additional doses of covid-19 vaccine are recommended for immunocompromised patients, especially for organ transplant recipients who are least able to make antibodies to fight off coronavirus, suggests new research https://t.co/l2IWfSb0zd @sundar__raghav
— The BMJ (@bmj_latest) March 3, 2022
M-A: Use of tocilizumab and sarilumab alone or in combination with corticosteroids for covid-19.
3 Mar, 2022 | 08:49h | UTCEditorial: Treatment of severe covid-19 with interleukin 6 receptor inhibition – BMJ Medicine
Related study (just published): Mortality Rates Among Hospitalized Patients With COVID-19 Infection Treated With Tocilizumab and Corticosteroids: A Bayesian Reanalysis of a Previous Meta-analysis – JAMA Network Open
M-A: Evaluation of budesonide-formoterol for maintenance and reliever therapy among patients with poorly controlled asthma.
3 Mar, 2022 | 07:59h | UTC
Prescribing Nirmatrelvir–Ritonavir for Covid-19: How to recognize and manage drug–drug interactions.
2 Mar, 2022 | 09:01h | UTCRelated:
Pfizer antiviral pills may be risky with other medications – NBC News
Anticoagulation in Patients With COVID-19: JACC Review Topic of the Week.
2 Mar, 2022 | 09:03h | UTCCommentary: Review of Anticoagulation in Patients With COVID-19: Key Points – American College of Cardiology
Review: Diagnosis and treatment of pulmonary sarcoidosis.
2 Mar, 2022 | 08:50h | UTCDiagnosis and Treatment of Pulmonary Sarcoidosis: A Review – JAMA (free for a limited period)
Related:
ERS clinical practice guidelines on treatment of sarcoidosis.
ATS Guideline: Diagnosis and Detection of Sarcoidosis
WASOG statement on the diagnosis and management of sarcoidosis-associated pulmonary hypertension.
Sarcoidosis: A clinical overview from symptoms to diagnosis.
Clinical Manifestations, Diagnosis, and Treatment of Sarcoidosis
New CDC interim guidance recommends a 4-month Rifapentine-Moxifloxacin regimen to treat drug-susceptible pulmonary tuberculosis.
27 Feb, 2022 | 22:49h | UTCRelated:
Summary | WHO recommendations on the treatment of drug-resistant tuberculosis, 2020 update.
WHO Guideline: Screening for Tuberculosis Disease
New WHO Recommendations to Prevent Tuberculosis
CDC Guidelines for the Treatment of Latent Tuberculosis Infection
Guideline: Treatment of Drug-Resistant Tuberculosis
The Lancet Commission: Management of Multidrug-resistant and Incurable Tuberculosis
Regimens to Treat Multidrug-resistant Tuberculosis: Past, Present and Future Perspectives
Guidelines for the Management of TB in Adults Living with HIV
Commentary on Twitter
Clinicians: @CDC_TB released interim guidance on a new regimen to treat #TB disease. Learn more about the 4-month regimen containing rifapentine, moxifloxacin, isoniazid, and pyrazinamide for people with drug-susceptible pulmonary TB disease in the U.S.: https://t.co/eOcR34tYJu pic.twitter.com/EFGMwAwN7c
— MMWR (@CDCMMWR) February 25, 2022
CDC issues long-awaited new guidance on when to wear masks.
27 Feb, 2022 | 22:45h | UTCCDC issues long-awaited new guidance on when to wear masks – STAT
See also: As mask mandates fade, experts say use of masks likely will not – STAT
ESCMID COVID-19 guidelines: diagnostic testing for SARS-CoV-2.
27 Feb, 2022 | 22:47h | UTCESCMID COVID-19 guidelines: diagnostic testing for SARS-CoV-2 – Clinical Microbiology and Infection
Guideline: Plasma exchange and glucocorticoid dosing for patients with ANCA-associated vasculitis.
27 Feb, 2022 | 22:40h | UTC
Commentary on Twitter
New rapid recommendation makes a weak recommendation against plasma exchange in patients with low risk of end stage kidney disease, and a weak recommendation in favour of plasma exchange in patients with moderate-high risk of ESKD https://t.co/PeEjSuRIxI #BMJInfographic pic.twitter.com/YR55t6XYhS
— The BMJ (@bmj_latest) February 25, 2022
Systematic Review: Effect of asthma education on health outcomes in children.
25 Feb, 2022 | 11:09h | UTC
Review: Safe tracheal extubation after general anesthesia.
25 Feb, 2022 | 11:03h | UTCSafe tracheal extubation after general anaesthesia – BJA Education
Two large populational-based studies find a slightly increased risk of thrombotic events following AstraZeneca COVID-19 vaccination.
24 Feb, 2022 | 10:23h | UTCCommentaries:
Two Large Studies Affirm Rare Thrombosis Risk With ChAdOx1 COVID-19 Vax – TCTMD
M-A: Diagnostic accuracy of point-of-care tests in acute community-acquired lower respiratory tract infections.
23 Feb, 2022 | 10:07h | UTC
Meta-analysis finds low risk of a second allergic reaction to SARS-CoV-2 mRNA vaccines in patients with an allergic reaction with the first dose.
22 Feb, 2022 | 10:05h | UTC
Commentary on Twitter
Systematic review and meta-analysis of 22 studies and 1366 patients found that there was a low risk of repeat allergic reaction to a second #COVID19 mRNA vaccine dose in people who had immediate allergic reaction with the first dose. https://t.co/NQSXBJwa6r
— JAMA Internal Medicine (@JAMAInternalMed) February 21, 2022
Opinion by Dr. Eric Topol | Why one-shot after a Covid-19 infection should suffice to be considered fully-vaxxed.
22 Feb, 2022 | 10:07h | UTCWhy one-shot after a Covid-19 infection should suffice to be considered fully-vaxxed – The Guardian
Commentary from the author on Twitter (thread – click for more)
My new essay @guardian
"Why one-shot after a Covid-19 infection should suffice to be considered fully-vaxxed"https://t.co/RaBUpET2CZ
Summarizes extensive new evidence that confirmed Prior Covid ("Natural Immunity" or NI) + 1-shot is as protective as 3-shots /1— Eric Topol (@EricTopol) February 20, 2022
[Preprint] A large-scale observational study in Chile found CoronaVac (an inactivated SARS-CoV-2 vaccine) was associated with an effectiveness of 74.5% against infection, 91.0% against hospitalization, and 93.8% against ICU admission in children aged 6 to 16 years.
22 Feb, 2022 | 09:58h | UTCCommentary: Full schedule of CoronaVac vaccine shown to be highly effective in children – News Medical
ESCMID rapid guidelines for assessment and management of long COVID.
21 Feb, 2022 | 09:31h | UTCRelated:
ERS statement on Long COVID-19 follow-up.
Proposed subtypes of long-Covid and their respective potential therapies.
EuGMS Guidance: Management of post-acute COVID-19 patients in geriatric rehabilitation.
Addressing Post-COVID Symptoms: A Guide for Primary Care Physicians.
Update to post-acute sequelae of SARS-CoV-2 infection: Caring for the ‘long-haulers’.
Systematic Review: Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection.
WHO Consensus: A clinical case definition of post COVID-19 condition (Long Covid).
Characterizing long COVID: a living systematic review.
Long Covid – The illness narratives.
New guidelines to help doctors manage long COVID patients published.
M-A: More than 50 long-term effects of COVID-19. (several articles on the subject)
RCT: In patients with mild to moderate Covid-19 and comorbidities, treatment with Ivermectin did not reduce the risk of disease progression.
21 Feb, 2022 | 09:34h | UTCCommentaries:
Ivermectin doesn’t prevent severe disease from Covid-19, new study finds – CNN
Ivermectin futile for mild to moderate COVID-19, study finds – CIDRAP
Related:
Case Series: Toxic effects from ivermectin use associated with prevention and treatment of Covid-19.
Long-term consequences of the misuse of ivermectin data.
Ivermectin: How false science created a Covid ‘miracle’ drug.
Fraudulent ivermectin studies open up new battleground between science and misinformation.
The lesson of ivermectin: meta-analyses based on summary data alone are inherently unreliable.
Ivermectin: Cochrane’s most talked about review so far, ever. Why?
Flawed ivermectin preprint highlights challenges of COVID drug studies.
Systematic review: no evidence to support the use of Ivermectin for treating or preventing COVID-19.
Why was a major study on ivermectin for covid-19 just retracted?
RCT: Ivermectin does not prevent hospitalizations in patients with COVID-19.
RCT: Ivermectin does not improve time to resolution of symptoms among adults with mild COVID-19
Review: Cancer-associated venous thromboembolism.
21 Feb, 2022 | 08:42h | UTCCancer-associated venous thromboembolism – Nature Reviews Disease Primers (if the link is paywalled, try this one)
Infographic: Cancer-associated venous thromboembolism – Nature Reviews Disease Primers (if the link is paywalled, try this one)
Related:
NCCN Guideline: Cancer-Associated Venous Thromboembolic Disease.
ASH 2021 guidelines for prevention and treatment of venous thromboembolism in patients with cancer
Review: venous and arterial thromboembolism in patients with cancer.